backgroundhuman
parainfluenza
viru
type
common
caus
upper
lower
respiratori
tract
ill
infant
young
children
liveattenu
coldadapt
vaccin
evalu
infant
suitabl
interv
administr
second
dose
vaccin
defin
children
age
month
random
blind
studi
receiv
two
dose
tcid
tissu
cultur
infecti
dose
liveattenu
recombin
coldpassag
human
vaccin
placebo
month
apart
serum
antibodi
level
assess
prior
approxim
week
dose
vaccin
viru
infect
defin
detect
nasal
wash
andor
rise
serum
antibodi
titer
reactogen
assess
day
follow
immun
resultsforti
children
median
age
month
rang
month
enrol
receiv
vaccin
receiv
placebo
infect
detect
evalu
vaccine
follow
dose
subject
follow
dose
among
shed
viru
median
durat
viral
shed
day
rang
day
dose
day
rang
day
dose
mean
peak
log
viral
titer
pfuml
sd
dose
compar
pfuml
sd
dose
overal
reactogen
mild
differ
rate
fever
upper
respiratori
infect
symptom
vaccin
placebo
group
immunogen
welltoler
seroneg
young
children
second
dose
administ
month
initi
dose
restrict
previous
infect
vaccin
viru
howev
second
dose
boost
antibodi
respons
induc
antibodi
respons
two
previous
uninfect
children
human
parainfluenza
viru
type
import
caus
respiratori
diseas
infant
young
children
respons
upper
respiratori
diseas
well
lower
respiratori
tract
diseas
includ
bronchiol
pneumonia
human
parainfluenza
virus
hpiv
type
associ
substanti
burden
diseas
children
overal
result
frequent
medic
care
hospit
pediatr
respiratori
diseas
alon
second
respiratori
syncyti
viru
rsv
caus
bronchiol
pneumonia
infant
less
month
age
patient
age
underli
pulmonari
diseas
immunocompromis
condit
may
seriou
diseas
relat
hpiv
import
among
virus
current
licens
vaccin
antivir
therapi
avail
prevent
treatment
hpiv
diseas
liveattenu
vaccin
develop
undergon
clinic
test
past
sever
decad
use
intranas
rout
administr
liveattenu
viral
vaccin
may
offer
advantag
immun
hpiv
young
children
includ
potenti
induct
mucos
system
immun
infect
liveattenu
influenza
viru
vaccin
one
dose
liveattenu
vaccin
may
need
induc
sustain
protect
infant
young
children
two
approach
develop
liveattenu
vaccin
taken
relat
anim
viru
bovin
use
creat
chimer
human
bovin
vaccin
addit
liveattenu
vaccin
candid
human
strain
deriv
via
repeat
passag
low
temperatur
attenu
design
extens
evalu
phase
ii
clinic
trial
children
infant
young
one
month
age
recent
cdnaderiv
recombin
version
biologicallyderiv
vaccin
develop
design
vaccin
contain
known
attenu
mutat
present
biologicallyderiv
viru
use
cdna
approach
advantag
use
viru
short
wellcharacter
passag
histori
well
abil
readili
regener
modifi
viru
need
vaccin
recent
evalu
phase
trial
infant
age
month
random
receiv
two
dose
vaccin
placebo
administ
week
apart
safeti
profil
infect
first
dose
similar
previous
observ
biologicallyderiv
viru
second
dose
vaccin
highli
restrict
replic
boost
serum
antibodi
respons
reason
explor
whether
extend
interv
dose
might
enhanc
infect
immunogen
second
dose
vaccin
purpos
studi
determin
toler
infect
immunogen
two
tcid
dose
administ
month
apart
seroneg
infant
children
experiment
vaccin
live
recombin
r
deriv
attenu
human
h
viru
genet
phenotyp
compar
extens
evalu
biolog
deriv
vaccin
vaccin
previous
evalu
infant
young
month
age
seed
viru
product
experiment
vaccin
gener
laboratori
infecti
diseas
lid
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
md
clinic
lot
vaccin
viru
prepar
charl
river
laboratori
malvern
pa
clinic
lot
lot
test
steril
infect
sequenc
ident
safeti
anim
presenc
adventiti
agent
lot
pass
test
satisfactorili
vaccin
viru
store
frozen
mean
infect
titer
tissu
cultur
infecti
dose
tcid
per
ml
final
vial
content
dilut
dose
onsit
random
doubleblind
placebocontrol
outpati
trial
enrol
seroneg
subject
age
month
random
ratio
receiv
dose
vaccin
placebo
respect
clinicaltrialsgov
identifi
studi
purpos
studi
defin
hemagglutin
inhibit
hai
serum
antibodi
titer
inclus
criteria
young
children
particip
trial
includ
good
state
health
uptod
routin
immun
parent
legal
guardian
will
abl
sign
inform
consent
children
exclud
particip
known
suspect
reactiv
airway
diseas
major
congenit
malform
impair
immunolog
function
receiv
immunosuppress
therapi
recipi
solid
organ
bone
marrow
transplant
live
home
environ
young
infant
month
age
sever
immunosuppress
famili
member
previous
immun
vaccin
known
hypersensit
vaccin
compon
children
born
hivinfect
women
elig
child
confirm
hivuninfect
children
recent
fever
f
acut
upper
respiratori
ill
recent
acut
otiti
media
receiv
liveattenu
routin
vaccin
within
week
inactiv
routin
vaccin
within
week
receiv
system
steroid
antibiot
histori
prematur
week
gestat
age
year
defer
later
enrol
children
screen
antibodi
within
day
prior
enrol
enrol
seroneg
children
random
receiv
dose
tcid
vaccin
viru
placebo
qualifi
leibovitz
medium
lonza
walkersvil
md
approxim
month
apart
figur
subject
random
receiv
dose
vaccin
dose
placebo
use
predetermin
random
scheme
assign
unblind
pharmaci
laboratori
dispens
volum
ml
vaccin
placebo
deliv
via
nose
drop
ml
per
nostril
blind
studi
nurs
use
steril
needleless
syring
subject
supin
immedi
dose
subject
remain
supin
approxim
second
observ
advers
event
minut
serum
collect
prior
first
dose
immedi
prior
second
dose
week
second
dose
nasal
wash
perform
prior
inocul
day
day
follow
inocul
dose
describ
infect
phenotyp
stabil
vaccin
viru
assess
studi
visit
collect
nasal
wash
specimen
subject
monitor
day
follow
inocul
respiratori
febril
ill
addit
physic
examin
nasal
wash
collect
event
respiratori
febril
ill
parent
studi
staff
monitor
temperatur
daili
use
phillip
sensor
thermomet
tempor
arteri
thermomet
screen
elev
temperatur
tempor
temperatur
f
verifi
obtain
rectal
temperatur
within
minut
use
standard
thermomet
provid
studi
prior
immun
ill
symptom
report
nasal
wash
obtain
test
adventiti
agent
viral
cultur
andor
rrtpcr
test
fasttrack
diagnost
luxembourg
lower
respiratori
tract
infect
lri
defin
confirm
wheez
rale
pneumonia
croup
rhonchi
radiolog
evid
pneumonia
categor
seriou
advers
event
regardless
sever
written
inform
consent
obtain
parent
legal
guardian
studi
particip
prior
screen
enrol
studi
conduct
accord
principl
declar
helsinki
standard
good
clinic
practic
defin
intern
confer
harmon
studi
perform
niaidheld
investig
new
drug
applic
bbind
review
us
food
drug
administr
clinic
protocol
consent
form
investigatorbrochur
develop
cir
schri
impaact
niaid
investig
review
approv
institut
respect
institut
review
board
well
niaid
regulatori
complianc
human
subject
protect
branch
rchspb
clinic
data
regularli
review
clinic
niaid
investig
data
safeti
monitor
board
niaid
divis
clinic
research
nasal
wash
perform
use
steril
nasal
bulb
syring
ml
lactat
ringer
solut
instil
child
nare
aliquot
nasal
wash
snap
frozen
sucrosephosphateglutam
viral
transport
medium
previous
describ
store
primari
viru
isol
quantit
aliquot
nasal
wash
rapidli
thaw
inocul
onto
cell
incub
cir
laboratori
titer
vaccin
viru
express
tissuecultur
infecti
dose
tcid
per
ml
nasal
wash
fluid
lower
limit
detect
tcid
ml
differenti
infect
vaccin
viru
intercurr
natur
infect
wildtyp
wt
nucleotid
sequenc
perform
isol
obtain
peak
viru
shed
children
shed
either
dose
vaccin
viru
isol
produc
inocul
nasal
wash
onto
cell
harvest
supernat
day
later
viral
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
valencia
ca
cdna
gener
use
superscript
firststrand
synthesi
system
rtpcr
invitrogen
carlsbad
ca
sampl
cdna
amplifi
clontech
advantag
hf
pcr
kit
clontech
mountain
view
ca
gener
pcr
product
cover
segment
f
gene
nucleotid
contain
two
attenu
mutat
encod
val
thr
dna
purifi
use
high
pure
pcr
product
purif
kit
roch
diagnost
mannheim
germani
sequenc
perform
use
abi
bigdy
appli
biosystem
foster
citi
ca
sequenc
nasal
wash
specimen
obtain
prior
inocul
day
rang
day
rang
day
rang
day
time
respiratori
febril
ill
test
adventiti
viral
agent
either
viral
cultur
revers
transcript
realtim
polymeras
chain
reaction
assay
rrtpcr
fasttrack
diagnost
luxembourg
test
adventiti
agent
includ
follow
coronaviru
adenoviru
enteroviru
parechoviru
respiratori
syncyti
viru
ab
parainfluenza
virus
type
human
metapneumoviru
ab
bocaviru
mycoplasma
pneunomina
serum
specimen
store
frozen
use
sera
test
antibodi
hai
antibodi
test
method
start
serum
dilut
dilut
increment
endpoint
titrat
infect
vaccin
viru
defin
either
isol
vaccin
viru
rise
antibodi
titer
mean
peak
titer
vaccin
viru
shed
log
tcid
ml
durat
last
day
shed
calcul
infect
vaccine
data
analyz
use
stata
stata
corp
colleg
station
tx
haireciproc
titer
transform
log
valu
calcul
mean
log
titer
student
test
use
compar
hai
titer
group
baselin
data
ill
rate
group
compar
use
independ
sampl
unequ
varianc
ttest
continu
variabl
fisher
exact
test
categor
variabl
total
infant
young
children
enrol
studi
figur
median
age
month
rang
month
subject
random
receiv
vaccin
receiv
first
dose
median
age
month
rang
month
receiv
second
dose
median
age
month
rang
month
placebo
recipi
receiv
first
second
dose
median
age
month
rang
month
month
rang
month
respect
signific
differ
age
vaccin
gender
racial
ethnic
profil
vaccin
placebo
group
tabl
thirtynin
subject
receiv
two
dose
vaccin
n
placebo
n
thirtynin
blood
sampl
obtain
follow
first
vaccin
dose
second
vaccin
dose
median
durat
particip
subject
week
rang
week
studi
followup
excel
one
subject
lost
followup
vaccin
well
toler
studi
subject
seriou
advers
event
relat
studi
vaccin
report
subject
specif
lower
respiratori
tract
diseas
respiratori
ill
requir
medic
attent
consid
relat
studi
vaccin
occur
throughout
trial
rate
fever
differ
significantli
vaccin
placebo
group
follow
either
dose
dose
studi
drug
rate
similar
vaccin
placebo
group
follow
vaccin
dose
tabl
mild
upper
respiratori
sign
symptom
common
follow
dose
vaccin
placebo
tabl
cough
uncommon
occur
vaccin
recipi
first
dose
vaccin
otiti
media
document
follow
first
dose
studi
drug
one
vaccin
recipi
first
document
day
one
placebo
recipi
first
document
day
rate
ill
differ
significantli
follow
first
second
dose
vaccin
similar
vaccin
placebo
recipi
p
respect
dose
dose
nasal
wash
obtain
particip
test
adventiti
agent
day
prior
vaccin
studi
drug
nasal
wash
also
obtain
test
potenti
adventiti
agent
symptomat
subject
vaccin
recipi
placebo
recipi
follow
dose
symptomat
subject
vaccin
recipi
placebo
recipi
follow
dose
tabl
virus
detect
vaccin
recipi
follow
dose
vaccin
follow
dose
virus
detect
placebo
recipi
dose
dose
virus
identifi
nasal
wash
specimen
follow
dose
nasal
wash
specimen
follow
dose
common
adventiti
agent
detect
throughout
studi
rhinoviru
dose
dose
note
adventiti
agent
detect
vaccine
placebo
recipi
throughout
studi
includ
adenovirus
bocavirus
coronavirus
enterovirus
rhinovirus
shed
vaccin
viru
document
children
follow
first
dose
vaccin
follow
second
dose
p
tabl
median
durat
viral
shed
infect
vaccin
viru
day
rang
day
follow
first
dose
compar
day
rang
day
follow
second
dose
vaccin
peak
mean
log
titer
follow
first
dose
pfu
ml
sd
compar
pfuml
sd
follow
second
dose
p
fourfold
greater
increas
serum
antibodi
document
evalu
children
follow
first
dose
vaccin
mean
log
hai
antibodi
titer
six
children
follow
second
dose
mean
log
antibodi
titer
time
first
dose
vaccin
age
vaccin
recipi
infect
dose
month
sd
significantli
older
infect
dose
month
sd
among
vaccin
recipi
higher
predos
antibodi
titer
less
like
shed
viru
p
mean
predos
antibodi
titer
shed
viru
sd
compar
mean
predos
antibodi
titer
shed
viru
mean
viral
antibodi
titer
sd
detect
one
placebo
recipi
begin
day
studi
prior
vaccin
isol
confirm
rtpcr
amplif
sequenc
analysi
wild
type
vaccin
viru
addit
vaccin
viru
isol
nasal
wash
sampl
vaccine
shed
dose
confirm
vaccin
viru
rtpcr
sequenc
isol
vaccine
contain
expect
mutat
data
shown
thu
confirm
viru
vaccin
deriv
attenu
mutat
maintain
vaccin
viru
replic
antibodi
respons
follow
vaccin
dose
shown
figur
major
studi
particip
greater
antibodi
rise
follow
first
dose
vaccin
subject
rise
titer
indic
natur
infect
dose
dose
mean
log
antibodi
titer
increas
significantli
entir
group
vaccine
second
vaccin
dose
increas
titer
observ
children
achiev
log
antibodi
titer
follow
first
dose
vaccin
thu
net
effect
second
dose
increas
proport
subject
achiev
rel
high
hai
antibodi
titer
wherea
children
achiev
postvaccin
log
titer
observ
follow
first
dose
vaccin
achiev
log
titer
follow
second
dose
one
evalu
vaccin
recipi
neither
seroconvers
viral
shed
document
overal
infect
defin
either
viral
shed
rise
antibodi
titer
observ
vaccin
children
follow
first
dose
follow
second
dose
vaccin
three
placebo
recipi
rise
hai
antibodi
titer
four
six
week
follow
first
dose
vaccin
includ
child
shed
wt
purpos
studi
determin
whether
increas
interv
dose
abl
enhanc
infect
second
dose
result
studi
confirm
initi
experi
vaccin
safe
welltoler
good
rate
infect
antibodi
respons
follow
singl
dose
vaccin
demonstr
children
substanti
antibodi
respons
follow
first
dose
vaccin
seem
abl
either
infect
boost
second
dose
administ
approxim
month
first
dose
contrast
second
dose
vaccin
given
six
month
later
appear
boost
antibodi
titer
suboptim
respons
follow
first
dose
associ
lower
amount
detect
viru
nasal
wash
interest
children
requir
second
dose
vaccin
achiev
antibodi
respons
significantli
younger
overal
studi
demonstr
two
dose
separ
month
abl
infect
children
three
year
age
infect
singl
dose
vaccin
expect
pediatr
trial
high
rate
infect
symptom
virus
common
rate
type
virus
symptom
similar
placebo
vaccin
group
emphas
need
placebocontrol
trial
detect
adventiti
agent
use
molecular
diagnost
techniqu
help
assess
potenti
causal
fever
subject
trial
sinc
mani
placebo
vaccin
recipi
fever
associ
infect
virus
trial
sinc
typic
circul
spring
summer
month
trial
conduct
sequenc
analysi
prove
use
tool
differenti
infect
wt
vaccin
viru
technolog
import
assess
safeti
reactogen
vaccin
conduct
clinic
trial
ill
placebo
recipi
abl
directli
relat
infect
potenti
spread
vaccin
viru
clinic
set
previou
clinic
studi
similar
hpiv
vaccin
shown
good
immunogen
exampl
studi
karron
et
al
adult
children
infant
reveal
infect
singl
dose
seroneg
children
age
month
use
dose
either
later
studi
bernstein
et
al
studi
recombin
vaccin
util
clinic
trial
infant
less
month
age
dose
vaccin
dose
younger
popul
viral
shed
dose
document
recipi
compar
older
popul
dose
bernstein
trial
either
serorespons
shed
occur
vaccin
recipi
compar
rate
infect
serorespons
shed
dose
dose
futur
use
vaccin
may
includ
immun
young
infant
potenti
repeat
dose
ensur
optim
immunogen
sinc
youngest
children
highest
risk
hospit
receiv
medic
care
group
would
natur
target
immun
provid
protect
diseas
addit
use
combin
liveattenu
rsv
human
metapneumoviru
hmpv
vaccin
envis
strategi
provid
broad
protect
import
respiratori
viral
pathogen
infanc
earli
childhood
dose
schedul
type
vaccin
would
need
harmon
current
pediatr
vaccin
schedul
vaccin
immunogen
welltoler
seroneg
young
children
second
dose
given
month
later
restrict
previous
infect
antibodi
respons
boost
second
dose
second
dose
induc
antibodi
respons
two
previous
uninfect
children
studi
design
depict
vaccin
recipi
particip
dose
studi
receiv
vaccin
dose
placebo
recipi
receiv
placebo
dose
dose
abbrevi
studi
day
nw
collect
nasal
wash
blood
draw
collect
sera
reciproc
hai
antibodi
level
dose
dose
individu
vaccin
recipi
clinic
virolog
respons
infant
children
follow
placebo
b
durat
shed
calcul
infect
subject
defin
time
inocul
last
day
vaccin
viru
recov
c
mean
peak
titer
viru
shed
calcul
infect
subject
vaccin
author
manuscript
avail
pmc
novemb
